Titre
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Griessbach, A.
Auteure/Auteur
Chammartin, F.
Auteure/Auteur
Abela, I.A.
Auteure/Auteur
Amico, P.
Auteure/Auteur
Stoeckle, M.P.
Auteure/Auteur
Eichenberger, A.L.
Auteure/Auteur
Hasse, B.
Auteure/Auteur
Braun, D.L.
Auteure/Auteur
Schuurmans, M.M.
Auteure/Auteur
Müller, T.F.
Auteure/Auteur
Tamm, M.
Auteure/Auteur
Audigé, A.
Auteure/Auteur
Mueller, N.J.
Auteure/Auteur
Rauch, A.
Auteure/Auteur
Günthard, H.F.
Auteure/Auteur
Koller, M.T.
Auteure/Auteur
Trkola, A.
Auteure/Auteur
Epp, S.
Auteure/Auteur
Amstutz, A.
Auteure/Auteur
Schönenberger, C.M.
Auteure/Auteur
Taji Heravi, A.
Auteure/Auteur
Papadimitriou-Olivgeris, M.
Auteure/Auteur
Casutt, A.
Auteure/Auteur
Manuel, O.
Auteure/Auteur
Kusejko, K.
Auteure/Auteur
Bucher, H.C.
Auteure/Auteur
Briel, M.
Auteure/Auteur
Speich, B.
Auteure/Auteur
Contributrices/contributeurs
I, A.
K, A.P.
A, A.
M, B.
E, B.
Dl, B.
Hc, B.
A, C.
M, C.
A, C.
G, D.
M, E.
L, E.
J, F.
J, F.
H, F.
Ca, F.
Hf, G.
A, H.
D, H.
B, H.
Hh, H.
M, H.
I, H.
M, H.
D, J.P.
Cr, K.
L, K.
O, K.
T, K.
Rd, K.
H, K.
K, K.
N, L.
K, L.
de Tejada B, M.
C, M.
Kj, M.
N, M.
J, N.
D, N.
J, N.
P, P.
G, P.
M, P.
A, R.
L, S.V.
P, S.
R, S.
M, S.
P, T.
A, T.
G, W.
M, W.
S, Y.
Amico, P.
Aubert, J.D.
Banz, V.
Beckmann, S.
Beldi, G.
Berger, C.
Berishvili, E.
Berzigotti, A.
Binet, I.
Bochud, P.Y.
Branca, S.
Bucher, H.
Catana, E.
Cairoli, A.
Chalandon, Y.
De Geest, S.
De Rougemont, O.
De Seigneux, S.
Dickenmann, M.
Dreifuss, J.L.
Duchosal, M.
Fehr, T.
Ferrari-Lacraz, S.
Garzoni, C.
Golshayan, D.
Goossens, N.
Haidar, F.
Halter, J.
Heim, D.
Hess, C.
Hillinger, S.
Hirsch, H.H.
Hirt, P.
Hoessly, L.
Hofbauer, G.
Huynh-Do, U.
Immer, F.
Koller, M.
Laesser, B.
Lamoth, F.
Lehmann, R.
Leichtle, A.
Manuel, O.
Marti, H.P.
Martinelli, M.
McLin, V.
Mellac, K.
Merçay, A.
Mettler, K.
Mueller, N.J.
Müller-Arndt, U.
Müllhaupt, B.
Nägeli, M.
Oldani, G.
Pascual, M.
Passweg, J.
Pazeller, R.
Posfay-Barbe, K.
Rick, J.
Rosselet, A.
Rossi, S.
Rothlin, S.
Ruschitzka, F.
Schachtner, T.
Schaub, S.
Scherrer, A.
Schnyder, A.
Schuurmans, M.
Schwab, S.
Sengstag, T.
Simonetta, F.
Stampf, S.
Steiger, J.
Stirnimann, G.
Stürzinger, U.
Van Delden, C.
Venetz, J.P.
Villard, J.
Vionnet, J.
Wick, M.
Wilhelm, M.
Yerly, P.
Groupes de travail
Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
Liens vers les personnes
Liens vers les unités
ISSN
2328-8957
Statut éditorial
Publié
Date de publication
2023-11
Volume
10
Numéro
11
Première page
ofad536
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third SARS-CoV-2 vaccine in patients with different levels of immunosuppression.
In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients). We collected blood samples before and 8 weeks after the third SARS-CoV-2 vaccination with either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech). The primary outcome was the proportion of participants showing an antibody response (Elecsys Anti-SARS-CoV-2 S test; threshold ≥100 U/mL) 8 weeks after the third SARS-CoV-2 vaccination. We also compared the proportion of patients who reached the primary outcome from basic immunization (the first and second vaccines) to the third vaccination.
Nearly all participants (97.2% [95% CI, 95.9%-98.6%], 564/580) had an antibody response. This response was comparable between mRNA-1273 (96.1% [95% CI, 93.7%-98.6%], 245/255) and BNT162b2 (98.2% [95% CI, 96.7%-99.6%], 319/325). Stratification by cohort showed that 99.8% (502/503) of people living with HIV and 80.5% (62/77) of recipients of solid organ transplants achieved the primary endpoint. The proportion of patients with an antibody response in solid organ transplant recipients improved from the second vaccination (22.7%, 15/66) to the third (80.5%, 62/77).
People living with HIV had a high antibody response. The third vaccine increased the proportion of solid organ transplant recipients with an antibody response. Clinical Trials Registration. NCT04805125 (ClinicalTrials.gov).
In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients). We collected blood samples before and 8 weeks after the third SARS-CoV-2 vaccination with either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech). The primary outcome was the proportion of participants showing an antibody response (Elecsys Anti-SARS-CoV-2 S test; threshold ≥100 U/mL) 8 weeks after the third SARS-CoV-2 vaccination. We also compared the proportion of patients who reached the primary outcome from basic immunization (the first and second vaccines) to the third vaccination.
Nearly all participants (97.2% [95% CI, 95.9%-98.6%], 564/580) had an antibody response. This response was comparable between mRNA-1273 (96.1% [95% CI, 93.7%-98.6%], 245/255) and BNT162b2 (98.2% [95% CI, 96.7%-99.6%], 319/325). Stratification by cohort showed that 99.8% (502/503) of people living with HIV and 80.5% (62/77) of recipients of solid organ transplants achieved the primary endpoint. The proportion of patients with an antibody response in solid organ transplant recipients improved from the second vaccination (22.7%, 15/66) to the third (80.5%, 62/77).
People living with HIV had a high antibody response. The third vaccine increased the proportion of solid organ transplant recipients with an antibody response. Clinical Trials Registration. NCT04805125 (ClinicalTrials.gov).
PID Serval
serval:BIB_AA0E2350DF22
PMID
Open Access
Oui
Date de création
2023-12-01T08:34:27.613Z
Date de création dans IRIS
2025-05-21T01:25:47Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
ofad536.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
400.98 KB
Format
Adobe PDF
PID Serval
serval:BIB_AA0E2350DF22.P001
URN
urn:nbn:ch:serval-BIB_AA0E2350DF223
Somme de contrôle
(MD5):2d9270661c9ff50950496fb04b3a095c